Lepu Biopharma (HKG:2157) has renewed a procurement agreement with controlling shareholder Lepu Medical Technology (SHE:300003) for one year from Jan. 1 to Dec. 31, 2025, a Tuesday bourse filing said.
Under the contract, Lepu Medical Technology, alongside its units and associates, will continue supplying raw materials and supplementary materials for clinical trials, biological sample test services for clinical trials, employee body check services, and other products to the company.
The current procurement framework agreement is due to expire Dec. 31, according to the drugmaker.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments